Decoy Therapeutics Regains Nasdaq Compliance, Enters One-Year Monitoring Period
Decoy Therapeutics regained compliance with Nasdaq Listing Rule 5550(a)(2) on March 31, 2026, satisfying the minimum bid price requirement and all other continued listing criteria. The company will undergo a one-year mandatory panel monitoring period during which any future noncompliance could trigger delisting proceedings.
1. Regained Nasdaq Compliance
On March 31, 2026, Decoy Therapeutics received notification that its shares had regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2), as well as all other applicable continued listing criteria of The Nasdaq Capital Market.
2. Mandatory Panel Monitoring
Nasdaq will subject Decoy to a mandatory panel monitoring period lasting one year from the compliance date, during which the Listing Qualifications Staff will review ongoing bid price levels and other listing factors to ensure continued adherence to listing standards.
3. Potential Delisting Risk
If Decoy fails to uphold the minimum bid price requirement during the monitoring period, Nasdaq will issue a delisting determination letter, and the company will have the opportunity to request a hearing with the Nasdaq Hearings Panel to contest any proposed delisting action.